Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Multiple sclerosis in 2014

Progress in MS—classification, mechanisms and treatment

Nature Reviews Neurology volume 11, pages 76–78 (2015)Cite this article

Subjects

Scientific progress in multiple sclerosis (MS) research spanned a number of areas in 2014, including therapeutics, disease classification, risk management, and disease mechanisms. Advances were particularly notable in the field of progressive MS. Altogether, the findings move us one step closer to a better understanding of this complex disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278–286 (2014).

    Article  PubMed  Google Scholar 

  2. Villar, L. M. et al. Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann. Neurol. 76, 231–240 (2014).

    Article  CAS  Google Scholar 

  3. Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383, 2213–2221 (2014).

    Article  CAS  Google Scholar 

  4. Calabresi, P. A. et al. Pegylated interferon β-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 13, 657–665 (2014).

    Article  CAS  Google Scholar 

  5. Okuda, D. T. et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS ONE 9, e90509 (2014).

    Article  PubMed  Google Scholar 

  6. Plavina, T. et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann. Neurol. 76, 802–812 (2014).

    Article  CAS  PubMed  Google Scholar 

  7. Spain, R. & Bourdette, D. The radiologically isolated syndrome: look (again) before you treat. Curr. Neurol. Neurosci. Rep. 11, 498–506 (2011).

    Article  Google Scholar 

  8. Schlaeger, R. et al. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann. Neurol. 76, 568–580 (2014).

    Article  PubMed  Google Scholar 

  9. Azevedo, C. J. et al. In vivo evidence of glutamate toxicity in multiple sclerosis. Ann. Neurol. 76, 269–278 (2014).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

J.O. holds the Decker Family Transitional Career Development Award from the Multiple Sclerosis Society of Canada.

Author information

Authors and Affiliations

  1. Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, M5B 1W8, ON, Canada

    Jiwon Oh & Paul W. O'Connor

Authors
  1. Jiwon Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul W. O'Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul W. O'Connor.

Ethics declarations

Competing interests

J.O. has received research funding from Genzyme and has received personal compensation for consulting or speaking from Biogen Idec, EMD Serono, Genzyme and Novartis. P.W.O. has received consulting fees and/or grant support from Actelion, Bayer, Biogen Idec, EMD Serono, Genentech, Novartis, Receptos, Roche, Sanofi–Genzyme and Teva.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oh, J., O'Connor, P. Progress in MS—classification, mechanisms and treatment. Nat Rev Neurol 11, 76–78 (2015). https://doi.org/10.1038/nrneurol.2014.259

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.259

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing